

TECHNICAL DATA SHEET

CyFlow™ CD55 PE-Cy5 Anti-Hu; Clone MEM-118

REF CK237219

For Research Use Only.

Not for use in diagnostic or therapeutic procedures.

Specifications

Antigen	CD55
Alternative Names	DAF
Clone	MEM-118
Clonality	monoclonal
Format	PE-Cy5
Host / Isotype	Mouse / IgM
Species Reactivity	Human, Non-Human Primates
Negative Species Reactivity	—
Quantity	100 tests
Immunogen	HPB-ALL human T cell line

Specificity

The mouse monoclonal antibody MEM-118 recognizes an epitope in SCR4 domain of CD55 antigen, a 60-70 kDa glycosylphosphatidylinositol (GPI)-anchored single chain glycoprotein. CD55 is widely expressed on hematopoietic and on many non-hematopoietic cells; it is weakly present on NK cells.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

Application

The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 4 µl reagent / 100 µl of whole blood or 10⁶ cells in a suspension. The content of a vial (0.4 ml) is sufficient for 100 tests.

Other usages may be determined from the scientific literature.

Storage Buffer

The reagent is provided in stabilizing Tris buffered saline (TBS) solution, pH ≈8.0, containing 0.1% (w/v) sodium azide.

Storage and Stability

Storage	Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
Stability	Do not use after expiration date stamped on vial label.

Background Information

CD55 (DAF; decay-accelerating factor) is a GPI-anchored membrane glycoprotein that protects autologous cells from classical and alternative pathway of complement cascade. Bidirectional interactions between CD55 and CD97 are involved in T cell regulation and CD55 can still regulate complement when bound to CD97. In tumors, besides protection against complement, CD55 promotes neoangiogenesis, tumorigenesis, invasiveness and evasion of apoptosis.

References

- Doussis IA, Gatter KC, Mason DY: CD68 reactivity of non-macrophage derived tumours in cytological specimens. J Clin Pathol. 1993 Apr; 46(4):334-6. < PMID: 7684403 >
- Angelisová P, Drbal K, Horejsí V, Cerný J: Association of CD10/neutral endopeptidase 24.11 with membrane microdomains rich in glycosylphosphatidylinositol-anchored proteins and Lyn kinase. Blood. 1999 Feb 15; 93(4):1437-9. < PMID: 10075459 >
- Miwa T, Maldonado MA, Zhou L, Sun X, Luo HY, Cai D, Werth VP, Madaio MP, Eisenberg RA, Song WC: Deletion of decay-accelerating factor (CD55 exacerbates autoimmune disease development in MRL/lpr mice. Am J Pathol. 2002 Sep; 161(3):1077-86. < PMID: 12213736 >

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com

- Mikesch JH, Buerger H, Simon R, Brandt B: Decay-accelerating factor (CD55): a versatile acting molecule in human malignancies. Biochim Biophys Acta. 2006 Aug; 1766(1):42-52. < PMID: 16784816 >
- Miwa T, Maldonado MA, Zhou L, Yamada K, Gilkeson GS, Eisenberg RA, Song WC: Decay-accelerating factor ameliorates systemic autoimmune disease in MRL/lpr mice via both complement-dependent and -independent mechanisms. Am J Pathol. 2007 Apr; 170(4):1258-66. < PMID: 17392165 >
- Abbott RJ, Spendlove I, Roversi P, Fitzgibbon H, Knott V, Teriete P, McDonnell JM, Handford PA, Lea SM: Structural and functional characterization of a novel T cell receptor co-regulatory protein complex, CD97-CD55. J Biol Chem. 2007 Jul 27; 282(30):22023-32. < PMID: 17449467 >
- VanLandingham JW, Cekic M, Cutler S, Hoffman SW, Stein DG: Neurosteroids reduce inflammation after TBI through CD55 induction. Neurosci Lett. 2007 Sep 25; 425(2):94-8. < PMID: 17826908 >

The Safety Data Sheet for this product is available at www.sysmex-partec.com/services.

Cy and CyDye are trademarks of GE Healthcare.

Contact Information:

Sysmex Partec GmbH • Am Flugplatz 13 • 02828 Görlitz • Germany
Tel +49 3581 8746 0 • Fax +49 3581 8746 70 • E-mail: info@sysmex-partec.com